NCT02006147 - Phase 1 Open-label Study to Evaluate Efficacy and Tolerability of TLC399 in Patients With Macular Edema Due to RVO | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

July 15, 2020

Study Completion Date

July 15, 2020

Conditions

Central Retinal Vein Occlusion With Macular EdemaBranch Retinal Vein Occlusion With Macular Edema

Interventions

DRUG

TLC399

Dose-escalation Study from 100 mM PL (20 µL) with 0.24 mg DSP to 100 mM PL (20 µL) with0.36 mg DSP to 100 mM PL (20 µL) with 0.6 mg DSP to 50 mM PL (10 µL) with 0.6 mg DSP.

Trial Locations (6)

Unknown

Changhua Christian Medical Foundation Changhua Christian Hospital, Chang-hua

Kaohsiung Veterans General Hospital, Kaohsiung City

National Taiwan University Hospital, Taipei

Shin Kong Wu Ho-Su Memorial Hospital, Taipei

Taipei Veterans General Hospital, Taipei

Chang Gung Memorial Hospital, Linkou Branch, Taoyuan District